ArticleAmerican journal of respiratory cell and molecular biology2012
Mycoplasma pneumoniae CARDS toxin induces pulmonary eosinophilic and lymphocytic inflammation.
Article in American journal of respiratory cell and molecular biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.
- The effects of macrolides in children with reactive airway disease: a systematic review and meta-analysis of randomized controlled trials.Drug design, development and therapy · 2018Pooled it
- Innate and adaptive immunity pathways linking Mycoplasma pneumoniae to pediatric asthma phenotypes.European journal of pediatrics · 2026Review
- Melatonin attenuates Mycoplasma pneumoniae-Induced Inflammation and barrier dysfunction by CXCL10/TLR4/STAT1 axis.Cell communication and signaling : CCS · 2026Article
- Risk factors and clinical characteristics of fulminant Mycoplasma pneumoniae pneumonia in children: a retrospective case‒control study.BMC infectious diseases · 2026Article
- The Post-Pandemic Return ofJournal of clinical medicine · 2026Article
- Bacterial Toxin Exploits Host Membrane Phospholipid as a Receptor for Binding, Entry, and Cytopathogenicity.Molecular microbiology · 2026Article
- Identification of Mycoplasma pneumoniae P1-interacting proteins by GST pull-down and analysis of its transcriptomic regulation in A549 cells.FEMS microbiology letters · 2026Article
- Clinical characteristics and prognostic factors of pediatric acute eosinophilic pneumonia: an 11-year single-center retrospective cohort study.European journal of pediatrics · 2026Article
- Immune dysregulation inFrontiers in immunology · 2026Review
- Multi-omics analysis of host airway responses in pediatric Mycoplasma pneumoniae pneumonia reveals potential mechanisms of disease exacerbation caused by co-infection.NPJ biofilms and microbiomes · 2025Article
- Correlation analysis between clinical characteristics of adult patients with Mycoplasma pneumoniae pneumonia and 23S rRNA A2063 gene in alveolar lavage fluid.BMC pulmonary medicine · 2025Article
- A comprehensive study based on machine learning models for early identification Mycoplasma pneumoniae infection in segmental/lobar pneumonia.Scientific reports · 2025Article
- Protective immunity induced by a novel P1 adhesin C-terminal anchored mRNA vaccine againstMicrobiology spectrum · 2025Article
- CCL20 Expression via AKT-ERK1/2-AP1 Pathway inJournal of inflammation research · 2025Article
- Rapid detection ofFrontiers in cellular and infection microbiology · 2025Article
- Whole-genome probe capture sequencing reveals genomic diversity and characteristics ofFrontiers in microbiology · 2025Article
- D-dimer serves as predictor of plastic bronchitis or necrotizing pneumonia in children withFrontiers in pediatrics · 2025Article
- Clinical features of Mycoplasma pneumoniae pneumonia in children without fever.BMC pediatrics · 2024Article
- Insights into the defensive roles of lncRNAs duringFrontiers in microbiology · 2024Review
- Respiratory microbiota imbalance in children with Mycoplasma pneumoniae pneumonia.Emerging microbes & infections · 2023Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Mycoplasma pneumoniae causes acute and chronic lung infections in humans, leading to a variety of pulmonary and extrapulmonary sequelae. Of the airway complications of M. pneumoniae infection, M. pneumoniae-associated exacerbation of asthma and pediatric wheezing are emerging as significant sources of human morbidity. However, M. pneumoniae products capable of promoting allergic inflammation are unknown. Recently, we reported that M. pneumoniae produces an ADP-ribosylating and vacuolating toxin termed the community-acquired respiratory distress syndrome (CARDS) toxin. Here we report that naive mice exposed to a single dose of recombinant CARDS (rCARDS) toxin respond with a robust inflammatory response consistent with allergic disease. rCARDS toxin induced 30-fold increased expression of the Th-2 cytokines IL-4 and IL-13 and 70- to 80-fold increased expression of the Th-2 chemokines CCL17 and CCL22, corresponding to a mixed cellular inflammatory response comprised of a robust eosinophilia, accumulation of T cells and B cells, and mucus metaplasia. The inflammatory responses correlate temporally with toxin-dependent increases in airway hyperreactivity characterized by increases in airway restriction and decreases in lung compliance. Furthermore, CARDS toxin-mediated changes in lung function and histopathology are dependent on CD4(+) T cells. Altogether, the data suggest that rCARDS toxin is capable of inducing allergic-type inflammation in naive animals and may represent a causal factor in M. pneumoniae-associated asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.